您好，欢迎来到仪器设备网！ [登录] [免费注册]
仪器设备网
发布求购
位置：首页 > 产品库 > C34
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
C34
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
C34图片
CAS NO:40592-88-9
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
C34 是一种口服活性 TLR4 抑制剂，可减少内毒素血症和坏死性小肠结肠炎模型中的全身炎症。
Cas No.40592-88-9
别名Toll-Like Receptor 4-C34
化学名3,4,6-triacetate-1-methylethyl 2-(acetylamino)-2-deoxy-α-D-glucopyranoside
Canonical SMILESCC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O
分子式C17H27NO9
分子量389.4
溶解度50mg/mL in ethanol or in DMF, 25mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
文献引用
产品描述

Toll-like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS), with LPS-binding protein, to initiate an innate immune response, which typically includes increased expression of TNFα.[1] TLR4-C34 is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages in vitro when used at 10 μM.[2],[3] It does not affect signaling through either TLR2 or TLR9. TLR4-C34, used at 1 mg/kg in vivo, also reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.[2] It markedly decreases the basal expression of TNFα, as well as LPS-induced iNOS and TNFα expression, in intestinal tissue isolated from patients with necrotizing enterocolitis.[2]

Reference:
[1]. Morris, M.C., Gilliam, E.A., and Li, L. Innate immune programing by endotoxin and its pathological consequences. Front.Immunol. 5, 1-8 (2015).
[2]. Neal, M.D., Jia, H., Eyer, B., et al. Discovery and validation of a new class of small molecule toll-like receptor 4 (TLR4) inhibitors. PLoS One 8(6), e65779 (2013).
[3]. Wipf, P., Eyer, B.R., Yamaguchi, Y., et al. Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4). Tetrahedron Letters 56(23), 3097-3100 (2015).